Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02423083 · ClinicalTrials.gov registry record · Phase 1
Oral Guanabenz for Multiple Sclerosis
A Phase 1 study, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02423083: Clinical Trial Phase 1 study, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
NCT02423083 is a Phase 1 study that was terminated before completion, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02423083, a Phase 1 study, was terminated before completion, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Background: \- People with multiple sclerosis (MS) get lesions in their brain and spinal cord. These cause neurological symptoms and sometimes disability. Researchers want to see if a blood pressure drug called guanabenz can repair lesions and help people with MS. Objective: \- To see if guanabenz is safe and well tolerated in people with MS. Eligibility: \- People 18 55 years old with MS who have taken glatiramer acetate for the past year. Design: * Participants will be screened in a separate protocol. For 2 months, they will be examined and have magnetic resonance imaging (MRI) scans. This will decide if they are in the Stable or Active MS study group. * The study will last 5 months. There will be up to 11 visits, 5 overnight. * Visit 1: overnight stay at the clinic: * Medical history and physical exam. * Health questionnaire * Bladder ultrasound scan * Brain MRI * Electrocardiogram (EKG) to measure heart electrical activity * Blood will be drawn through an intravenous (IV) line. * Participants may have tests of strength, muscle tone, and movement. * They will get their first dose of the study drug, a tablet taken once a day. * Participants will take the study drug at home and keep a medicine diary. * The dose will slowly increase. Each time, participants will stay overnight at the clinic. They will have a physical exam, EKG, MRI, and IV blood draw. * Visit 6: Participants will have a physical exam, MRI, and blood drawn. They will get a schedule to slowly lower their drug dose and stop taking guanabenz. * Participants will have 2 final visits. They will have a physical exam, EKG, MRI, and IV blood draw.
Interventions
- DRUG Guanabenz
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-04-21 |
| Est. Completion | 2017-10-30 |
| Phase | Phase 1 |
Why NCT02423083 stopped before completion
NCT02423083 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Guanabenz is the first listed.
NCT02423083 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02423083 about?
NCT02423083 is a clinical study titled "Oral Guanabenz for Multiple Sclerosis". Background: \- People with multiple sclerosis (MS) get lesions in their brain and spinal cord. These cause neurological symptoms and sometimes disability. Researchers want to see if a blood pressure drug called guanabenz can repair lesions and help people with MS. Objective: \- To see if guanaben...
What is the current status of trial NCT02423083?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2015-04-21. Estimated completion is 2017-10-30.
What interventions are being tested in trial NCT02423083?
The interventions under investigation include: Guanabenz (DRUG).
Who is sponsoring clinical trial NCT02423083?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02423083's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI